Taysha Gene Therapies Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Taysha Gene Therapies Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- TSHA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001806310
Board of directors
-
Alison S. Long · DirectorSince 2023
-
John A. Stalfort III · DirectorSince 2023
-
Kathleen Reape · DirectorSince 2023
-
Laura Sepp-Lorenzino · DirectorSince 2023
-
Phillip B. Donenberg · DirectorSince 2023
-
Sean P. Nolan · Director · Chief Executive OfficerSince 2023
-
Sukumar Nagendran · Director · President and Head of R&DSince 2023
Chief executives
Sean P. Nolan
· Chief Executive Officer
Dates unknown
Board connections
4 of this board's directors also sit on 5 other boards.
- via John A. Stalfort III
- via Sukumar Nagendran
- via Phillip B. Donenberg
- via Sean P. Nolan
- via John A. Stalfort III
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,695,906
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 1, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Option exercise | +260,047 | $1.71 | $444,680 |
| Dec 1, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −260,047 | $4.51 | $1,172,812 |
| Nov 28, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Option exercise | +70,172 | $0.70 | $49,120 |
| Nov 28, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Option exercise | +39,953 | $1.71 | $68,320 |
| Nov 28, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −110,125 | $4.75 | $523,094 |
| Sep 10, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Option exercise | +41,150 | $0.70 | $28,805 |
| Sep 10, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −200,000 | $3.23 | $646,000 |
| Aug 21, 2025 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −57,054 | $2.85 | $162,604 |
| Aug 21, 2025 | Alam Kamran Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −54,491 | $2.85 | $155,299 |
| Jun 2, 2025 | John A. Stalfort III Director | Grant or award | +56,623 | — | — |
| Jun 2, 2025 | Phillip B. Donenberg Director | Grant or award | +56,623 | — | — |
| Jun 2, 2025 | Alison S. Long Director | Grant or award | +56,623 | — | — |
| Jun 2, 2025 | Laura Sepp-Lorenzino Director | Grant or award | +56,623 | — | — |
| May 30, 2025 | Paul B. Manning 10% owner | Open-market purchase | +750,000 | $2.75 | $2,062,500 |
| Mar 11, 2025 | Alam Kamran Officer (CHIEF FINANCIAL OFFICER) | Shares withheld for tax | −29,843 | $1.69 | $50,435 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.